BI-1206 + rituximab

BI-1206 + rituximab is a combination therapy under clinical investigation for the treatment of non-Hodgkin's lymphoma and other B-cell malignancies. BI-1206 is a monoclonal antibody that targets Fc gamma receptor IIb (CD32b), an inhibitory immune checkpoint on B cells. By antagonizing this receptor, BI-1206 is designed to overcome resistance to anti-CD20 therapies like rituximab, restoring and enhancing their anti-tumor activity. Rituximab is a well-established monoclonal antibody targeting CD20 antigen on B cells, used in various lymphomas and leukemias. The combination aims to improve outcomes in patients who have relapsed or are refractory to prior rituximab-containing regimens. Clinical trials have shown promising responses, including complete and partial remissions in heavily pretreated patients[1][2][3][4][5][6].